Drug Discovery Services Market Size & Share 2023 to 2032
Market Size by Process (Hit-to-Lead Identification, Lead Optimization), Type (Chemistry Services, Biological) Drug Type (Small-molecule), Therapeutic Area (Oncology).
Report ID: GMI6004
|
Published Date: June 2023
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Drug Discovery Services Market size
Drug Discovery Services Market size accounted for USD 16.3 billion in 2022 and is estimated to grow at 14.1% CAGR between 2023 and 2032. Increasing R&D investments by government as well as by private players for novel drug discovery and development coupled with growing demand for novel therapies. For instance, in 2021, according to the Congressional Budget Office report, in 2019, the pharmaceutical sector spent USD 83 billion in R&D activities for development of novel therapies.
Drug Discovery Services Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Drug discovery services refer to specialized services encompass a range of activities and expertise required to identify, optimize, and develop potential drug candidates for evaluation and clinical testing. These drug discovery services help pharmaceutical and biotechnology companies augment their internal capabilities, access specialized expertise, accelerate the drug discovery process, and mitigate risks associated with developing new therapies.
COVID-19 Impact
The COVID-19 pandemic has severely impacted the global economies with all the sectors witnessing a significant slump during 2020. The healthcare sector was one of the most severely impacted sectors during the pandemic owing to tremendous pressure on the healthcare systems to contain the spread of infection. During the initial phase of the pandemic, slight slowdown was observed in some non-COVID-19-related drug discovery and research activities. Several companies were noted to revise their R&D spending for clinical trials in comparison to earlier spending. However, rapid recovery was observed due to the growing urge for the development of vaccine and effective drugs for the treatment of COVID-19.
Drug Discovery Services Market Trends
Escalating disease burden has created the demand for effective therapeutics and diagnostic solutions. The emergence of severe infectious disorders including COVID-19 and the Ebola pandemic has resulted in the rising need for R&D across the globe. Therefore, catering to such huge demand for novel drugs and treatment therapies, the companies are compelled to broaden their R&D capabilities with significant investments. Some of the leading pharmaceutical and medical device companies are noted to significantly increase spending on their research activities.
Drug Discovery Services Restraint
Stringent regulations governing drug discovery services may significantly hamper the drug discovery services market gains. The drug discovery process is subject to rigorous regulations and guidelines imposed by regulatory authorities to ensure safety, efficacy, and quality of new drugs. Compliance with complex regulatory requirements increases the time and cost involved in drug discovery and development. Furthermore, strict regulations can lead to longer approval timelines, higher development costs, and increased risk of regulatory hurdles. These factors can hamper innovation and investment in drug discovery, particularly for smaller companies with limited resources.
Drug Discovery Services Market Analysis
By process, the drug discovery services market is classified into target selection, target validation, hit-to-lead identification, lead optimization and candidate validation. The lead optimization segment accounted for 25.9% of the market share in 2022. Lead optimization is one of the critical processes in drug discovery services that involves refining and optimizing potential drug candidates to improve their efficacy, safety, and pharmacological properties. Furthermore, lead optimization aims to enhance the drug candidate's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion to enhance the drug bioavailability and therapeutic outcomes. Also, it contributes to reducing potential toxicity and adverse effects, making the drug candidate safer for use in humans.
Based on type, the drug discovery services market is segmented into chemistry services and biological services. The chemistry services are expected to register around USD 32.8 billion by 2032. Chemistry services in drug discovery involve the synthesis and analysis of chemical compounds to identify and optimize potential drug candidates. These services provide pharmaceutical and biotechnology companies with expertise in medicinal chemistry, synthesis of novel compounds and structure-activity relationship studies. Also, they enable the design and synthesis of diverse compound libraries for screening and identification of potential drug candidates.
By drug type, the drug discovery services market is segmented into small-molecule drugs and large-molecule drugs. The small-molecule drugs segment accounted for significant market revenue in 2022 and is expected to grow at 14.4% CAGR through 2032. Small-molecule drugs are widely used in the pharmaceutical industry owing to their oral bioavailability, diverse chemical structures, and favourable pharmacokinetic properties. Adoption of drug discovery services for small molecule drugs helps to identify and optimize small-molecule drug candidates with desirable properties such as potency, selectivity, and safety. They often have lower manufacturing costs and simple formulation requirements making them cost-effective to produce and distribute.
The therapeutic area in drug discovery services market is categorized into diabetes, neurology, oncology, infectious diseases, and other therapeutic areas. Oncology segment accounted for USD 4.3 billion market revenue in 2022. The rising burden of oncology will accelerate the adoption rate of drug discovery for novel cancer therapeutics. Drug discovery services in oncology provide specialized expertise, resources, and technologies to identify and develop innovative drugs targeting cancer. Furthermore, owing to the complexity of cancer and growing demand for targeted therapies, pharmaceutical companies are majorly focusing on drug discovery activities to accelerate drug discovery process and development of new cancer therapies.
The end-user in drug discovery services market is divided into pharmaceutical & biotechnology companies, contract research organizations and other end-users. Pharmaceutical & biotechnology companies segment accounted for nearly 69% market share in 2022. Pharmaceutical and biotechnology companies are the major end-users of drug discovery services, as these services enable to access a broader range of chemical libraries and screening platforms. The drug discovery service helps pharmaceutical and biotechnology to increase the chances of identifying potential drug candidates and enhance their product offerings.
North America drug discovery services market accounted for over 43.8% revenue share in 2022. The increasing prevalence of chronic disease and rising value for novel drugs is expected to boost the market growth. For instance, in 2020, according to the American Cancer Society, over 1.8 million new cancer cases were reported, and 606,520 people died of cancer in U.S. This has led to increasing demand for drug discovery services and novel therapeutics for oncology treatment. Furthermore, presence of major pharmaceutical and biotechnology companies and contract research organizations along with favorable regulatory environment.
Drug Discovery Services Market Share
Major business players operating in the drug discovery services market include:
Drug Discovery Services Industry News:
The drug discovery services market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Process
Type
Drug Type
Therapeutic Area
End-user
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →